Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Fate Therapeutics (NQ: FATE ) 4.405 +0.135 (+3.16%) Streaming Delayed Price Updated: 1:25 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Fate Therapeutics < Previous 1 2 3 4 5 6 7 8 9 Next > Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results February 15, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) February 02, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock January 29, 2024 Billionaire Steve Cohen is taking a massive stake in this little-known biotech company, leading FATE stock to surge more than 17%. Via InvestorPlace Analyst Ratings for Fate Therapeutics November 09, 2023 Via Benzinga Recap: Fate Therapeutics Q3 Earnings November 08, 2023 Via Benzinga Fate Therapeutics Inc. (NASDAQ: FATE) Near the Top of Equities by Percentage Gain on 9/18 September 18, 2023 Via Investor Brand Network Analyst Ratings for Fate Therapeutics September 07, 2023 Via Benzinga Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors January 08, 2024 From Fate Therapeutics, Inc. Via GlobeNewswire Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session January 03, 2024 U.S. stock futures were lower this morning, with the Dow Jones futures falling around 60 points on Wednesday. Shares of Pinstripes (NYSE: PNST) shares fell in pre-market trading after surging 22% on... Via Benzinga Topics Stocks Exposures US Equities Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 13, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire The Latest Analyst Ratings for Fate Therapeutics August 16, 2023 Via Benzinga Where Fate Therapeutics Stands With Analysts May 05, 2023 Via Benzinga Fate Therapeutics: Q1 Earnings Insights May 03, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session December 12, 2023 Via Benzinga Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates November 08, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm November 03, 2023 From Bragar Eagel & Squire Via GlobeNewswire Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results October 25, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire Fate Therapeutics to Present at Upcoming September Investor Conferences August 31, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm August 27, 2023 From Bragar Eagel & Squire Via GlobeNewswire Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates August 08, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire Stocks That Hit 52-Week Lows On Tuesday August 01, 2023 On Tuesday, 46 stocks hit new 52-week lows. Via Benzinga Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results July 28, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE June 30, 2023 From Kahn Swick & Foti, LLC Via Business Wire FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm June 21, 2023 From Bragar Eagel & Squire, P.C. Via Business Wire Why Shares of Fate Therapeutics Soared This Week June 16, 2023 The company's shares bounced back after a stock sale last week. Via The Motley Fool Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm June 08, 2023 From Bragar Eagel & Squire, P.C. Via Business Wire FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE June 05, 2023 From Kahn Swick & Foti, LLC Via Business Wire Fate Therapeutics to Present at Upcoming June Investor Conferences May 31, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire NASDAQ:FATE Long Term Investor Alert: Investigation of Potential Wrongdoing at Fate Therapeutics, Inc. May 24, 2023 San Diego, CA -- (SBWIRE) -- 05/24/2023 -- An investigation was announced for investors in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) concerning potential breaches of fiduciary duties by certain... Via SBWire Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates May 03, 2023 From Fate Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.